InstalabHDL Function Panel
Should you take a HDL Function Panel test?
This test is most useful if any of these apply to you.
7 Biomarkers Included
- HDLfx pCAD ScoreA composite score built from HDL-associated proteins that mirrors HDL function and links to coronary artery disease, giving a single summary of HDL-based risk.A high score suggests an HDL profile associated with coronary artery disease, even when standard lipids look acceptable.
- HDLfx pCECEstimates how effectively your HDL removes cholesterol from cells, the core protective job of HDL. This function often tracks heart risk more closely than the standard HDL cholesterol number.Low efflux capacity signals HDL that is present but not protective, a form of hidden cardiovascular risk.
- Apolipoprotein A1The main structural protein of HDL and a rough gauge of how many HDL particles you carry. It supports cholesterol removal but does not fully capture whether HDL works.Adequate levels alongside low efflux capacity suggest HDL that is plentiful but functionally impaired.
- Apolipoprotein C1A minor HDL protein that influences fat metabolism and cholesterol transfer between particles, adding to the composite reading of HDL composition.Shifts help characterize whether HDL cargo leans protective or dysfunctional within the overall score.
- Apolipoprotein C2A protein that switches on the enzyme breaking down triglycerides. Its balance against apolipoprotein C3 helps describe how efficiently your body clears fat from the blood.An unfavorable balance with apolipoprotein C3 suggests impaired triglyceride clearance.
- Apolipoprotein C3A small protein that, when enriched on lipoprotein particles, slows clearance of triglyceride-rich fats and is linked to higher cardiovascular risk.Elevated levels point toward triglyceride-driven risk and dysfunctional HDL rather than simply low HDL.
- Apolipoprotein C4A less common apolipoprotein involved in triglyceride handling that contributes to the protein pattern feeding the composite HDL function score.It adds to the overall protein signature rather than carrying a strong standalone meaning.
About HDL Function Panel
For years, a higher HDL number was treated as a win. Large studies have since shown that raising HDL cholesterol with drugs did not prevent heart attacks, and that the amount of HDL you carry says little about whether it works. What matters more is function.
This panel looks at HDL quality instead of quantity. It measures how well your HDL pulls cholesterol out of cells and reads the mix of proteins riding on those particles, both of which track heart risk that a basic lipid panel can miss.
What This Panel Reveals
HDL's main protective job is cleanup. It works like a shuttle, pulling excess cholesterol out of cells in your artery walls and carrying it back toward the liver, the first step of what scientists call reverse cholesterol transport. How efficiently your HDL does this is called cholesterol efflux capacity, and this panel estimates it directly through a marker labeled pCEC.
That cleanup ability tracks heart risk more tightly than the HDL number itself. In one large population study, people in the top quarter of efflux capacity had a 67 percent lower rate of cardiovascular events than those in the bottom quarter, while the standard HDL cholesterol number showed no such link once other risk factors were accounted for. In other research, higher efflux was tied to lower odds of coronary disease even after adjusting for HDL cholesterol and its main protein. The evidence is not uniform, though. Some large pooled analyses have found that efflux capacity no longer predicts coronary disease once HDL cholesterol and standard risk factors are taken into account, so this marker refines a risk picture rather than settling it.
HDL is not one thing. Each particle carries a shifting cargo of proteins that helps decide whether it behaves as protective or dysfunctional. The panel measures the main structural protein, apolipoprotein A1, along with four smaller passengers, apolipoproteins C1 through C4. Apolipoprotein C3 stands out: when it accumulates on particles, it is linked to slower clearance of triglyceride-rich fats and higher cardiovascular risk.
The panel also reports a composite score, HDLfx pCAD, that combines these proteins into a single readout tied to coronary artery disease, the narrowing of the vessels that feed the heart. It was built from a protein pattern that closely mirrors directly measured efflux capacity, offering a summary of HDL-based risk in one figure.
How to Read Your Results Together
No single marker here is meant to stand alone. The value comes from reading function, protein cargo, and your standard lipids side by side. A few patterns are worth recognizing.
| Pattern | What It Suggests |
|---|---|
| Normal HDL cholesterol but low pCEC | HDL is present in quantity but not doing its cleanup job, a form of hidden risk a basic panel misses. |
| Low pCEC with a high pCAD score | HDL function points toward a coronary-risk profile worth pairing with particle testing and possibly imaging. |
| Adequate apolipoprotein A1 but elevated apolipoprotein C3 | The HDL protein cargo has shifted toward a dysfunctional, triglyceride-linked pattern. |
| High HDL cholesterol with high pCEC | Reassuring HDL quality, though not a reason to ignore LDL or particle count. |
One caution runs through all of it. These markers refine risk; they do not override your LDL cholesterol or apolipoprotein B, the count of cholesterol-carrying particles that remains the strongest lipid target for treatment.
What to Do with Your Results
If your efflux capacity is low or your pCAD score leans toward elevated risk, treat it as a signal to sharpen the rest of your picture rather than a diagnosis. Pair it with apolipoprotein B and lipoprotein(a) to gauge particle-driven risk, and consider hs-CRP, a marker of inflammation that tends to run higher when HDL turns dysfunctional.
An elevated apolipoprotein C3 alongside high triglycerides points toward triglyceride-rich lipoprotein biology, where diet, blood sugar control, and in some cases medication matter more than chasing the HDL number. A cardiologist or lipid specialist can fold these results into an overall plan, ideally alongside coronary imaging if your risk looks meaningful. Because these are function and protein measures, serial tracking is best done thoughtfully: retesting every 6 to 12 months after a real change to diet, weight, or therapy can show whether your HDL quality is moving, though no validated retesting interval has been established.
When Results Can Be Misleading
Several things shift these markers at once. Active infection, recent illness, or a flare of inflammation can remodel HDL into a temporarily dysfunctional state, lowering efflux and altering the protein mix. A recent heavy meal raises triglycerides and can distort the apolipoprotein C signal, so a morning fasting draw gives the cleanest read.
The larger caveat is maturity. Efflux capacity and the apolipoprotein C markers are not yet standardized across laboratories, and no major medical society recommends them for routine screening. They add texture to a risk picture; they are not a substitute for standard lipids or a basis for treatment decisions on their own.